
Alkyl Amines Analyst Review 2027: Profit Up 52% in Q2, but Coverage Is Thin and the Stock Is 24% Off Its High
Updated: 18 Nov 2026 • 9:39 am
Posted by:

Alkyl Amines Chemicals Stock Snapshot (17 Nov 2026 close)
- Current Market Price (CMP): ₹1,610.10
- 52-Week High / Low: ₹2,115.00 / ₹1,212.00
- Market Capitalisation: ₹8,234 crore
- P/E Ratio vs Industry P/E: 33.3 vs 36.4
- Latest Quarter (Q2 FY27) Revenue: ₹490.95 crore
- Latest Quarter (Q2 FY27) Net Profit: ₹65.17 crore
Quick Answer: The Alkyl Amines analyst review 2027 starts with a clear earnings recovery but limited research coverage. Q2 FY27 revenue rose about 26% to ₹490.95 crore and profit rose about 52% to ₹65.17 crore, after a 91% profit jump in Q1. No recent named brokerage target could be verified, so there is no reliable published Alkyl Amines share price target 2027. At ₹1,610.10, the stock trades about 24% below its 52-week high and at a P/E near 33, slightly below its industry.
The Alkyl Amines analyst review 2027 covers India's leading maker of aliphatic amines, chemicals used by pharma, agrochemical and water treatment companies. Readers looking for an Alkyl Amines share price target 2027 should know that brokerage coverage is thin, so this review leans on reported results and the industry cycle.
Alkyl Amines Chemicals closed at ₹1,610.10 on 17 November 2026, about 24% below its 52-week high of ₹2,115 and about 33% above its low of ₹1,212. This Alkyl Amines analyst review 2027 covers what the numbers show, how the business works and the Alkyl Amines stock outlook 2027.
Click Here – Get Free Investment Predictions
What Analysts Say in the Alkyl Amines Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| No verified recent coverage | Not available | Not available | As of November 2026 |
No dated brokerage report with a rating and target from FY27 could be traced for Alkyl Amines. Institutional ownership is low, with foreign and domestic institutions together holding under 7%, and the company does not draw the same research attention as larger chemical makers.
That shapes how to read the Alkyl Amines analyst review 2027. Without consensus estimates, each quarterly result moves the stock more than usual. Any target that circulates without a named, registered source should be treated with caution.
What can be tracked is the earnings trend. Profit has risen sharply in both quarters of FY27 after a weak FY26, when the company described results as broadly flat and proposed a ₹10 per share dividend.
Q2 FY27 Results in the Alkyl Amines Analyst Review 2027
| Metric | Q2 FY27 | Q1 FY27 |
|---|---|---|
| Revenue from Operations | ₹490.95 crore (+26.1% YoY) | ₹528 crore (+30.2% YoY) |
| Net Profit | ₹65.17 crore (+51.8% YoY) | About ₹94.6 crore (+91% YoY) |
| Profit Before Tax | ₹90.09 crore | Not used here |
| H1 FY27 Revenue | ₹1,039.03 crore | |
| H1 FY27 Net Profit | ₹159.80 crore | |
Revenue from operations rose about 26.1% to ₹490.95 crore in Q2 FY27, and profit rose about 51.8% to ₹65.17 crore. Profit before tax was ₹90.09 crore. Profit grew about twice as fast as revenue, which points to better pricing and plant utilisation.
Compared with the June quarter, revenue and profit were lower. Q1 FY27 revenue was about ₹528 crore and profit about ₹94.6 crore, with EBITDA margin near 25.3%. For the Alkyl Amines analyst review 2027, the trend is still strong year on year, but the sequential dip is worth watching. H1 FY27 profit of ₹159.80 crore is already a large share of what a normal full year has looked like.
How Alkyl Amines Makes Money
Alkyl Amines, founded in 1979 by Yogesh Kothari, makes aliphatic amines and related chemicals at plants in Maharashtra and Gujarat.
- Methylamines and ethylamines: base chemicals used across pharma and agrochemical synthesis.
- Amine derivatives: higher-value products made from basic amines.
- Specialty chemicals: products for water treatment, rubber chemicals, solvents and other uses.
- Exports: a share of sales goes to global customers in pharma and agrochemicals.
Profit depends on the spread between selling prices and raw material costs such as methanol, ammonia and ethanol. When supply from China rises, prices fall and margins shrink. When demand recovers, the operating gains can be large, as FY27 so far shows. This sensitivity to the cycle is the core of the Alkyl Amines analyst review 2027.
Growth Triggers in the Alkyl Amines Analyst Review 2027
- Cycle recovery: two quarters of strong profit growth suggest the amine downcycle has eased.
- Sector peers: Balaji Amines also reported revenue up about 36% in Q2 FY27, which supports a broad recovery view.
- Pharma and agro demand: both end markets are recovering after inventory cuts.
- Balance sheet: debt to equity of about 0.01 means almost no borrowings.
- Return on equity: about 15%, which should rise if FY27 profit holds near the H1 run rate, a key test in the Alkyl Amines analyst review 2027.
Key Risks in the Alkyl Amines Analyst Review 2027
- Chinese supply: fresh capacity or dumping can push amine prices down quickly.
- Raw material swings: methanol and ammonia costs affect margins each quarter.
- Sequential slowdown: Q2 FY27 profit was lower than Q1 FY27.
- No research coverage: no named targets exist to anchor expectations.
- Low institutional base: institutions hold under 7%, so liquidity depends on retail holders.
- Valuation after recovery: a P/E near 33 already prices in part of the upturn.
Compare Alkyl Amines With Specialty Chemical Stocks on the Univest Screener
Alkyl Amines Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (17 Nov 2026 close) | ₹1,610.10 |
| 52-Week High / Low | ₹2,115.00 / ₹1,212.00 |
| Market Capitalisation | ₹8,234 crore |
| P/E (TTM) vs Industry | 33.3 vs 36.4 |
| Price to Book | 5.02 |
| Book Value per Share | ₹320.95 |
| Return on Equity | 15.07% |
| Debt to Equity | 0.01 |
| Dividend Yield | 0.62% |
| EPS (TTM) | ₹48.38 |
The stock trades at a slight discount to its industry P/E, with a price to book value of about 5. Trailing earnings include the weak second half of FY26, so the multiple would fall if FY27 profit holds near the H1 pace. In the Alkyl Amines analyst review 2027, valuation looks reasonable only if the recovery lasts.
Shareholding Trend
| Holder | Sep 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters | 72.03% | 72.04% | +0.01 pts |
| Foreign Investors (FII) | 3.43% | 3.46% | +0.03 pts |
| Domestic Institutions (DII) | 2.88% | 3.26% | +0.38 pts |
| Public | 21.66% | 21.24% | -0.42 pts |
The promoter group holds a steady 72.04%, with founder Yogesh Kothari at 57.64%. Institutional holdings barely moved over the year. A rise in institutional buying would be an early signal that the recovery story in the Alkyl Amines analyst review 2027 is gaining wider acceptance.
What to Watch After the Alkyl Amines Analyst Review 2027
- Q3 FY27 margins: whether profit growth stays strong after the dip from Q1 to Q2.
- Amine prices: trends in Chinese export prices for key amines.
- Raw materials: methanol and ammonia cost movements.
- Full-year profit: whether FY27 beats FY26 by a wide margin, given H1 profit of ₹159.80 crore.
- Research coverage: a first named note would give an Alkyl Amines share price target 2027 reference point.
Final Word on the Alkyl Amines Analyst Review 2027
The Alkyl Amines analyst review 2027 shows a debt-free chemical maker in the middle of a cyclical recovery, with Q2 FY27 profit up about 52% and H1 profit at ₹159.80 crore. The stock still trades about 24% below its high, and there is no verified brokerage target to guide expectations.
The Alkyl Amines stock outlook 2027 depends on amine prices, raw material costs and whether margins hold through the second half. Univest does not give a buy or sell call.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Alkyl Amines analyst review 2027 show?
It shows a strong earnings recovery with limited research coverage. Q2 FY27 revenue rose about 26.1% to ₹490.95 crore and profit rose about 51.8% to ₹65.17 crore. No recent named brokerage target could be verified.
Is there an Alkyl Amines share price target 2027 from brokerages?
No verified recent brokerage target exists as of November 2026. Institutions hold under 7% of the company, which limits research interest. The stock closed at ₹1,610.10 on 17 November 2026.
How did Alkyl Amines perform in H1 FY27?
H1 FY27 revenue was ₹1,039.03 crore and profit was ₹159.80 crore. Q1 profit rose about 91% and Q2 profit rose about 52% from a year earlier. Q2 profit was lower than Q1 on a sequential basis.
What does Alkyl Amines make?
It makes aliphatic amines such as methylamines and ethylamines, plus derivatives and specialty chemicals. These go into pharma, agrochemicals, water treatment and rubber chemicals. The company was founded in 1979 by Yogesh Kothari.
Is Alkyl Amines expensive, based on the Alkyl Amines analyst review 2027?
The P/E of about 33.3 is slightly below the industry figure of about 36.4. Price to book is about 5 and return on equity is about 15%. Trailing earnings include the weak second half of FY26.
What risks does the Alkyl Amines analyst review 2027 highlight?
The main risks are Chinese supply pushing amine prices down and swings in methanol and ammonia costs. Q2 FY27 profit was lower than Q1. There is also no named research coverage to anchor expectations.
What should investors track after the Alkyl Amines analyst review 2027?
Track Q3 FY27 margins and whether profit growth continues. Watch Chinese amine export prices and raw material costs. Full-year FY27 profit against the H1 figure of ₹159.80 crore is the main test.
Recent Articles

Andhra Paper Analyst Review 2027: Back to Profit in Q2, Stock at 0.64 Times Book and a Pollution Penalty Under Appeal
18 November 2026

Amrutanjan Analyst Review 2027: Q2 Profit Up 24%, Hygiene Grows Fast and the Stock Sits Near Its Low
18 November 2026

Amines and Plasticizers Analyst Review 2027: Profit Up 35% in Q2, Thin Margins and Zero Institutional Holding
18 November 2026

Alok Industries Analyst Review 2027: Revenue Up 15%, Loss Widens to ₹208 Crore and Net Worth Stays Negative
18 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Andhra Paper Analyst Review 2027: Back to Profit in Q2, Stock at 0.64 Times Book and a Pollution Penalty Under Appeal
Amrutanjan Analyst Review 2027: Q2 Profit Up 24%, Hygiene Grows Fast and the Stock Sits Near Its Low
Amines and Plasticizers Analyst Review 2027: Profit Up 35% in Q2, Thin Margins and Zero Institutional Holding
Alok Industries Analyst Review 2027: Revenue Up 15%, Loss Widens to ₹208 Crore and Net Worth Stays Negative
Allied Digital Analyst Review 2027: Revenue Up 14%, Profit Down 18% and the Stock Below Book Value
Popular this week
Allcargo Logistics Analyst Review 2027: A Smaller, Domestic Company After the Split, With Profit Back at ₹18 Crore

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





